Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration
Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK
The American journal of clinical nutrition · 219 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-06-01 · Am J Clin Nutr · vol. 87 · número 6 · págs. 1952–1958
- Editorial
- Elsevier BV
- Citado
- 332 citas · más que el 100% de estudios similares · 22.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Nutrition and Health Studies · Bone health and osteoporosis research
- Palabras clave
- vitamin D3 supplementation, 25-hydroxyvitamin D, vitamin D intake, dose-response relationship, hypercalcemia, hypercalciuria, vitamin D status, dose simulation
- MeSH
- humans, calcium, vitamin d, placebos, glomerular filtration rate, double-blind method, dose-response relationship, drug, algorithms, research design, reference values, adolescent, adult, aged, middle aged, female, male, white people, black people
8 autores
- John F. Aloia🇺🇸 · autor de correspondenciaWinthrop-University Hospital
- Manish Ramesh Patel🇺🇸Winthrop-University Hospital
- Rhett DiMaano🇺🇸Winthrop-University Hospital
- Melissa Li‐Ng🇺🇸Winthrop-University Hospital
- Sonia A Talwar🇺🇸Winthrop-University Hospital
- Mageda Mikhail🇺🇸Winthrop-University Hospital
- Simcha Z Pollack🇺🇸Winthrop-University Hospital
- James K. Yeh🇺🇸Winthrop-University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Indirect evidence suggests that optimal vitamin D status is achieved with a serum 25-hydroxyvitamin D [25(OH)D] concentration >75 nmol/L.
Objective
We aimed to determine the intake of vitamin D(3) needed to raise serum 25(OH)D to >75 nmol/L.
Design
The design was a 6-mo, prospective, randomized, double-blinded, double-dummy, placebo-controlled study of vitamin D(3) supplementation. Serum 25(OH)D was measured by radioimmunoassay. Vitamin D(3) intake was adjusted every 2 mo by use of an algorithm based on serum 25(OH)D concentration.
Results
A total of 138 subjects entered the study. After 2 dose adjustments, almost all active subjects attained concentrations of 25(OH)D >75 nmol/L, and no subjects exceeded 220 nmol/L. The mean (+/-SD) slope at 9 wk [defined as 25(OH)D change/baseline dose] was 0.66 +/- 0.35 (nmol/L)/(microg/d) and did not differ statistically between blacks and whites. The mean daily dose was 86 microg (3440 IU). The use of computer simulations to obtain the most participants within the range of 75-220 nmol/L predicted an optimal daily dose of 115 microg/d (4600 IU). No hypercalcemia or hypercalciuria was observed.
Conclusions
Determination of the intake required to attain serum 25(OH)D concentrations >75 nmol/L must consider the wide variability in the dose-response curve and basal 25(OH)D concentrations. Projection of the dose-response curves observed in this convenience sample onto the population of the third National Health and Nutrition Examination Survey suggests a dose of 95 microg/d (3800 IU) for those above a 25(OH)D threshold of 55 nmol/L and a dose of 125 microg/d (5000 IU) for those below that threshold.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.